Oculis' eye drug meets main goal in study (updated)

Oculis Holding AG

22/05/2023 12:43

(Repeats to widen distribution with no changes to text,
headline)
       May 22 (Reuters) - Oculis Holding  OCS.O  said on Monday
its drug to treat a type of eye disorder met its main goal in a
late-stage study, sending its shares up about 15% in premarket
trading.
        The company is testing the drug, ‍OCS-01​, to treat
diabetic macular edema which is a  leading cause of blindness in
patients with diabetes.
  
        Patients treated with the drug showed strong visual gain
compared to a vehicle, which is similar to a placebo, Oculis
said.
  
        OCS-01 was well-tolerated in the study and the company
plans to begin a second part of its late-stage study later this
year. 
  
        
    
     
  

 (Reporting by Bhanvi Satija and Pratik Jain in Bengaluru;
Editing by Janane Venkatraman and Nivedita Bhattacharjee)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))